8 [56] M. Soda, Y. L. Choi, M. Enomoto et al., “Identiﬁcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer,” Nature, vol. 448, no. 7153, pp. 561–566, 2007. [57] K. Rikova, A. Guo, Q. Zeng et al., “Global survey of phospho- tyrosine signaling identiﬁes oncogenic kinases in lung cancer,” Cell, vol. 131, no. 6, pp. 1190–1203, 2007. [58] Y. L. Choi, K. Takeuchi, M. Soda et al., “Identiﬁcation of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer,” Cancer Research, vol. 68, no. 13, pp. 4971– 4976, 2008. [59] A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson et al., “Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4247–4253, 2009. [60] X. Zhang, S. Zhang, X. Yang et al., “Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression,” Molecular Cancer, vol. 9, article no. 188, 2010. [61] J. M. Boland, S. Erdogan, G. Vasmatzis et al., “Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non- small cell lung carcinomas,” Human Pathology, vol. 40, no. 8, pp. 1152–1158, 2009. [62] B. Solomon, M. Varella-Garcia, and D. R. Camidge, “ALK gene rearrangements: a new therapeutic target in a molecularly deﬁned subset of non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 4, no. 12, pp. 1450–1454, 2009. [63] S. Perner, P. L. Wagner, F. Demichelis et al., “EML4-ALK fusion lung cancer: a rare acquired event,” Neoplasia, vol. 10, no. 3, pp. 298–302, 2008. [64] M. Salido, L. Pijuan, L. Mart´ınez-Avile´s et al., “Increased ALK gene copy number and ampliﬁcation are frequent in non- small cell lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 21–27, 2011. [65] M. Soda, S. Takada, K. Takeuchi et al., “A mouse model for EML4-ALK-positive lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19893–19897, 2008. [66] E. L. Kwak, Y. J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010. [67] Y. Sakairi, T. Nakajima, K. Yasufuku et al., “EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration,” Clinical Cancer Research, vol. 16, no. 20, pp. 4938–4945, 2010. [68] M. P. Martelli, G. Sozzi, L. Hernandez et al., “EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues,” American Journal of Pathology, vol. 174, no. 2, pp. 661–670, 2009. [69] M. Mino-Kenudson, L. R. Chirieac, K. Law et al., “A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immuno- histochemistry,” Clinical Cancer Research, vol. 16, no. 5, pp. 1561–1571, 2010. [70] K. Takeuchi, Y. L. Choi, Y. Togashi et al., “KIF5B-ALK, a novel fusion oncokinase identiﬁed by an immunohistochemistry- based diagnostic system for ALK-positive lung cancer,” Clin- ical Cancer Research, vol. 15, no. 9, pp. 3143–3149, 2009. [71] V. K. Anagnostou, A. W. Welsh, J. M. Giltnane et al., “Ana- lytic variability in immunohistochemistry biomarker studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 4, pp. 982–991, 2010. Pathology Research International [72] J. Bordeaux, A. W. Welsh, S. Agarwal et al., “Antibody validation,” BioTechniques, vol. 48, no. 3, pp. 197–209, 2010. [73] D. R. Camidge, S. A. Kono, A. Flacco et al., “Optimizing the detection of lung cancer patients harboring anaplastic lym- phoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment,” Clinical Cancer Research, vol. 16, no. 22, pp. 5581–5590, 2010. [74] M. H. Cohen, R. Justice, and R. Pazdur, “Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer,” Oncologist, vol. 14, no. 9, pp. 930– 935, 2009. [75] M. H. Cohen, P. Cortazar, R. Justice, and R. Pazdur, “Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung can- cer (NSCLC),” Oncologist, vol. 15, no. 12, pp. 1352–1358, 2010. [76] M. H. Cohen, J. Gootenberg, P. Keegan, and R. Pazdur, “FDA drug approval summary: bevacizumab (Avastin ) plus carboplatin and paclitaxel as ﬁrst-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer,” Oncologist, vol. 12, no. 6, pp. 713–718, 2007. [77] S. L. Edwards, C. Roberts, M. E. McKean, J. S. Cockburn, R. R. Jeﬀrey, and K. M. Kerr, “Preoperative histological classiﬁcation of primary lung cancer: accuracy of diagnosis and use of the non-small cell category,” Journal of Clinical Pathology, vol. 53, no. 7, pp. 537–540, 2000. [78] W. D. Travis, E. Brambilla, M. Noguchi et al., “International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidis- ciplinary classiﬁcation of lung adenocarcinoma,” Journal of Thoracic Oncology, vol. 6, no. 2, pp. 244–285, 2011. [79] R. W. Field, B. J. Smith, C. E. Platz et al., “Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review,” Journal of the National Cancer Institute, vol. 96, no. 14, pp. 1105–1107, 2004. [80] P. S. Loo, S. C. Thomas, M. C. Nicolson, M. N. Fyfe, and K. M. Kerr, “Subtyping of undiﬀerentiated non-small cell carcinomas in bronchial biopsy specimens,” Journal of Thoracic Oncology, vol. 5, no. 4, pp. 442–447, 2010. [81] B. Z. Ring, R. S. Seitz, R. A. Beck et al., “A novel ﬁve- antibody immunohistochemical test for subclassiﬁcation of lung carcinoma,” Modern Pathology, vol. 22, no. 8, pp. 1032– 1043, 2009. [82] R. Aharonov, D. Lebanony, H. Benjamin et al., “Diagnostic assay based on hsa-miR-205 expression distinguishes squa- mous from nonsquamous non-small-cell lung carcinoma,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2030–2037, 2009. [83] J. A. Bishop, H. Benjamin, H. Cholakh, A. Chajut, D. P. Clark, and W. H. Westra, “Accurate classiﬁcation of non-small cell lung carcinoma using a novel microRNA-based approach,” Clinical Cancer Research, vol. 16, no. 2, pp. 610–619, 2010.